Your browser doesn't support javascript.
loading
Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial.
Lu, Shun; Pan, Hongming; Wu, Lin; Yao, Yu; He, Jianxing; Wang, Yan; Wang, Xiuwen; Fang, Yong; Zhou, Zhen; Wang, Xicheng; Cai, Xiuyu; Yu, Yan; Ma, Zhiyong; Min, Xuhong; Yang, Zhixiong; Cao, Lejie; Yang, Huaping; Shu, Yongqian; Zhuang, Wu; Cang, Shundong; Fang, Jian; Li, Kai; Yu, Zhuang; Cui, Jiuwei; Zhang, Yang; Li, Man; Wen, Xinxuan; Zhang, Jie; Li, Weidong; Shi, Jianhua; Xu, Xingxiang; Zhong, Diansheng; Wang, Tao; Zhu, Jiajia.
Affiliation
  • Lu S; Department of Medical Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, 200030, Shanghai, China. shunlu@sjtu.edu.cn.
  • Pan H; Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, 310016, Hangzhou, China. panhongming@zju.edu.cn.
  • Wu L; Department of Thoracic Medical Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University (Hunan Cancer Hospital), 410031, Changsha, China.
  • Yao Y; Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, 710061, Xian, China.
  • He J; Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, 510120, Guangzhou, China.
  • Wang Y; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China.
  • Wang X; Department of Oncology, Qilu Hospital of Shandong University, 250012, Jinan, China.
  • Fang Y; Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, 310016, Hangzhou, China.
  • Zhou Z; Department of Medical Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, 200030, Shanghai, China.
  • Wang X; Department of Oncology, The First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University, 510699, Guangzhou, China.
  • Cai X; Department of Medical Oncology, Sun Yat-sen University Cancer Center, 510060, Guangzhou, China.
  • Yu Y; Department of Respiratory Medicine, Harbin Medical University Cancer Hospital, 150081, Harbin, China.
  • Ma Z; Department of Medical Oncology, Henan Tumor Hospital, 450003, Zhengzhou, China.
  • Min X; Department of Oncology Radiotherapy, Anhui Chest Hospital, 230022, Hefei, China.
  • Yang Z; Department of Cancer Center, Affiliated Hospital of Guangdong Medical University, 524000, Zhanjiang, China.
  • Cao L; Department of Respiratory Medicine, The First Affiliated Hospital of the University of Science and Technology of China, Anhui Provincial Hospital, 230031, Hefei, China.
  • Yang H; Department of Respiratory and Critical Care Medicine, Xiangya Hospital Central South University, 410008, Changsha, China.
  • Shu Y; Department of Cancer Center, Jiangsu Province Hospital, 210029, Nanjing, China.
  • Zhuang W; Department of Thoracic Oncology, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, 350014, Fuzhou, China.
  • Cang S; Department of Medical Oncology, Henan Province People's Hospital, 450003, Zhengzhou, China.
  • Fang J; Department of Thoracic Oncology, Peking University Cancer Hospital, 100142, Beijing, China.
  • Li K; Department of Pulmonary Oncology, Tianjin Medical University Cancer Institute and Hospital, 300060, Tianjin, China.
  • Yu Z; Department of Oncology, The Affiliated Hospital of Qingdao University, 266000, Qingdao, China.
  • Cui J; Department of Oncology, The First Hospital of Jilin University, 130061, Changchun, China.
  • Zhang Y; Department of Medical Oncology, The Second Hospital of Dalian Medical University, 116023, Dalian, China.
  • Li M; Department of Medical Oncology, The Second Hospital of Dalian Medical University, 116023, Dalian, China.
  • Wen X; Department of Oncology, Xiangyang No. 1 People's Hospital, 441011, Xiangyang, China.
  • Zhang J; Department of Respiratory and Critical Care Medicine, The Second Hospital of Jilin University, 130041, Changchun, China.
  • Li W; Department of Medical Oncology, Affiliated Cancer Hospital and Institute of Guangdong Medical University, 510095, Guangzhou, China.
  • Shi J; Department of Oncology, Linyi Cancer Hospital, 276002, Linyi, China.
  • Xu X; Department of Respiratory and Critical Care Medicine, Northern Jiangsu People's Hospital, 225001, Yangzhou, China.
  • Zhong D; Department of Medical Oncology, Tianjin Medical University General Hospital, 300052, Tianjin, China.
  • Wang T; Biostatistics Department of Clinical Center of Research Institute, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 222000, Nanjing, China.
  • Zhu J; Biostatistics Department of Clinical Center of Research Institute, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., 222000, Nanjing, China.
Signal Transduct Target Ther ; 8(1): 249, 2023 06 30.
Article in En | MEDLINE | ID: mdl-37385995
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Guideline Limits: Humans Language: En Journal: Signal Transduct Target Ther Year: 2023 Document type: Article Affiliation country: China Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Type of study: Guideline Limits: Humans Language: En Journal: Signal Transduct Target Ther Year: 2023 Document type: Article Affiliation country: China Country of publication: United kingdom